The insider liquidated 7,500 shares at a weighted average price of $82.02. The disposition represented 2% of the executive's total reported equity holdings.

fool.com - 2026-07-14 17:20:21

CYTK enters a new era after Myqorzos FDA approval, with early US uptake, European expansion and lifecycle studies fueling its commercial momentum.

zacks.com - 2026-07-10 15:11:07

IWN delivered a 37.4% one-year return but carries higher fees, while ISCV offers a 0.06% expense ratio and stronger dividend yield of 1.9%.

fool.com - 2026-07-07 07:40:01

Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic Cardiomyopathy

globenewswire.com - 2026-07-07 07:30:00

Entertainment leader Sphere stock continues to outperform in the current market environment, setting new highs.

investors.com - 2026-06-26 14:40:22

Large-cap pharma is back in the deal market. AbbVie's (NASDAQ: ABBV | ABBV Price Prediction) pending acquisition of Apogee Therapeutics signaled that big buyers will pay up for de-risked clinical assets.

247wallst.com - 2026-06-25 08:15:12

SOUTH SAN FRANCISCO, Calif., June 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 15, 2026 it granted stock options to purchase an aggregate of 24,784 shares of common stock and 16,429 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting and 2,242 performance stock units (PSUs) that, if earned, will be settled in shares of common stock upon vesting to 12 employees, whose employment commenced in May and June, 2026, as a material inducement to their employment.

globenewswire.com - 2026-06-17 16:00:00

CYTK has gained 18.4% YTD as Myqorzo's FDA approval, early launch momentum, and expanding market opportunities fuel investor interest.

zacks.com - 2026-06-17 11:56:04

Cytokinetics, Incorporated (CYTK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-09 03:58:30

Program to Provide Donations to Non-Profit Organizations Aligned with Corporate Values Deadline for Applications is August 3, 2026 SOUTH SAN FRANCISCO, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for its annual Cytokinetics Corporate Giving Program.

globenewswire.com - 2026-06-08 07:30:00

Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock?

zacks.com - 2026-06-04 12:36:49

European Launch Follows Strong U.S. Start SOUTH SAN FRANCISCO, Calif., and ZUG, Switzerland, June 01, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the first commercial European launch of MYQORZO® (aficamten) in Germany for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients.

globenewswire.com - 2026-06-01 07:30:00

SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following investor conferences in June:

globenewswire.com - 2026-05-27 16:00:00

Cytokinetics, Incorporated (CYTK) Shareholder/Analyst Call Prepared Remarks Transcript

seekingalpha.com - 2026-05-27 15:47:04

Cytokinetics NASDAQ: CYTK executives said the commercial launch of MYKORZO is tracking ahead of internal expectations, while also highlighting positive physician feedback on the drug's label, REMS program and recent clinical data in hypertrophic cardiomyopathy during a discussion hosted by RBC Capital Markets.

marketbeat.com - 2026-05-22 16:04:23

SOUTH SAN FRANCISCO, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 27, 2026 at 10:00 AM Pacific Time at the Company's headquarters, 350 Oyster Point Blvd., South San Francisco, CA. Immediately after the conclusion of the Annual Meeting of Stockholders, Robert I. Blum, President and Chief Executive Officer, is scheduled to present an overview of Cytokinetics' performance.

globenewswire.com - 2026-05-20 16:00:00

SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 15, 2026 it granted stock options to purchase an aggregate of 20,807 shares of common stock and 13,793 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 8 employees, whose employment commenced in April and May 2026 as a material inducement to their employment.

globenewswire.com - 2026-05-18 16:00:00

Third Annual Muscle Biology-Focused Research Symposium  Highlighting Recent Innovations in the Field SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company will host the third annual Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) on Friday, May 29, 2026 from 8:00 AM to 5:00 PM Pacific Time.

globenewswire.com - 2026-05-14 07:30:00

SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026 at 3:35 PM Eastern Time in New York, NY.

globenewswire.com - 2026-05-12 16:00:00

SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the presentation of new data reinforcing the clinical profile of MYQORZO® (aficamten) at the European Society of Cardiology (ESC) Heart Failure 2026 Congress. The presentations include new analyses from SEQUOIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with oHCM; MAPLE-HCM, the Phase 3 clinical trial of aficamten compared to metoprolol in patients with symptomatic obstructive HCM (oHCM); and FOREST-HCM, the open-label extension trial of aficamten.

globenewswire.com - 2026-05-11 10:06:00

SOUTH SAN FRANCISCO, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the closing of an underwritten public offering of 11,338,028 shares of its common stock, including the full exercise of the underwriters' option to purchase up to 1,478,873 additional shares, at a price to the public of $71.00 per share, before underwriting discounts and commissions. The gross proceeds to Cytokinetics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Cytokinetics, were approximately $805 million. All of the shares of common stock in the offering were sold by Cytokinetics.

globenewswire.com - 2026-05-08 10:51:00

SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the pricing of an underwritten public offering of 9,859,155 shares of its common stock at a price to the public of $71.00 per share, before underwriting discounts and commissions. The gross proceeds to Cytokinetics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Cytokinetics, are expected to be approximately $700 million. The offering is expected to close on May 8, 2026, subject to customary closing conditions. Additionally, Cytokinetics has granted the underwriters a 30-day option to purchase up to an additional 1,478,873 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock in the offering will be sold by Cytokinetics.

globenewswire.com - 2026-05-06 23:00:00

SOUTH SAN FRANCISCO, Calif. , May 06, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the pricing of an underwritten public offering of 9,859,155 shares of its common stock at a price to the public of $71. 00 per share, before underwriting discounts and commissions. The gross proceeds to Cytokinetics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Cytokinetics, are expected to be approximately $700 million.

globenewswire.com - 2026-05-06 23:00:00

Cytokinetics posts Q1 loss as Myqorzo launch lifts revenues to $19.4M, signaling commercial shift amid rising SG&A tied to rollout and expansion.

zacks.com - 2026-05-06 16:25:41

Cytokinetics, Incorporated (CYTK) Q1 2026 Earnings Call Prepared Remarks Transcript

seekingalpha.com - 2026-05-05 22:41:17

Cytokinetics (CYTK) came out with a quarterly loss of $1.67 per share in line with the Zacks Consensus Estimate. This compares to a loss of $1.36 per share a year ago.

zacks.com - 2026-05-05 19:05:37

SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced plans to offer, subject to market and other conditions, approximately $650 million of shares of its common stock in an underwritten public offering.

globenewswire.com - 2026-05-05 16:15:00

U.S. Launch of MYQORZO ® (aficamten) in Late January Met with Strong Demand; Over 275 HCPs Prescribed MYQORZO to an estimated 680 Patients in Q1 ACACIA-HCM Met Dual Primary Endpoints of KCCQ and Maximal Exercise Performance; Full Results to be Presented at Upcoming Medical Congress MYQORZO Approved by the European Commission for Adults with Symptomatic Obstructive HCM;Supplemental NDA for MAPLE-HCM Accepted for Filing by FDA with PDUFA Date of November 14, 2026 Net Product Revenues for MYQORZO of $4.8 Million for Initial Partial Quarter; ~$1.1 Billion in Cash, Cash Equivalents and Investments as of March 31, 2026 SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported a management update and financial results for the first quarter of 2026.

globenewswire.com - 2026-05-05 16:05:00

Cytokinetics, Incorporated (CYTK) Discusses ACACIA-HCM Topline Results From Pivotal Phase 3 Trial of Aficamten in Non-Obstructive HCM Transcript

seekingalpha.com - 2026-05-05 13:41:19

Cytokinetics ​said on ‌Tuesday ​its ​experimental drug ⁠to ​treat ​a type ​of ​heart disease met ‌the ⁠main goals ​in ​a ⁠late-stage ​trial.

reuters.com - 2026-05-05 07:35:17

Trial Met Dual Primary Endpoints of KCCQ and Maximal Exercise Performance  With Consistent Positive Findings Across Key Secondary Endpoints

globenewswire.com - 2026-05-05 07:30:00

Company to Host Conference Call and Webcast Tuesday May 5 at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced it will report topline results from ACACIA-HCM (Assessment Comparing A ficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM) on Tuesday, May 5, 2026.

globenewswire.com - 2026-05-04 16:00:00

Artificial intelligence has dominated investor attention for two years, but biotech revenue lines are also bending sharply higher.

247wallst.com - 2026-05-03 09:30:31

SOUTH SAN FRANCISCO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced nine presentations at the European Society of Cardiology Heart Failure 2026 Congress taking place in Barcelona, Spain, from May 9–12, 2026. Eight presentations, including a late-breaking science oral presentation, are related to MYQORZO® (aficamten). Recently approved for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) by the U.S. Food and Drug Administration, European Commission, and the China National Medical Products Administration, MYQORZO is an allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition with MYQORZO reduces cardiac contractility and consequently, left ventricular outflow tract (LVOT) obstruction.

globenewswire.com - 2026-04-28 07:30:00

SOUTH SAN FRANCISCO, Calif. , April 28, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced nine presentations at the European Society of Cardiology Heart Failure 2026 Congress taking place in Barcelona, Spain, from May 9-12, 2026. Eight presentations, including a late-breaking science oral presentation, are related to MYQORZO (aficamten).

globenewswire.com - 2026-04-28 07:30:00

SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 5, 2026 at 4:00 PM Eastern Time.

globenewswire.com - 2026-04-21 16:00:00

SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on April 15, 2026 it granted stock options to purchase an aggregate of 49,358 shares of common stock and 32,734 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 33 employees, whose employment commenced in March and April 2026 as a material inducement to their employment.

globenewswire.com - 2026-04-20 16:00:00

CYTK enters the commercial stage with FDA-approved Myqorzo for oHCM, eyeing strong market share, but faces stiff competition and execution risks.

zacks.com - 2026-04-17 14:40:27

Cytokinetics (NASDAQ: CYTK) executives outlined early commercialization efforts for MYQORZO and previewed several upcoming clinical and regulatory milestones during a fireside chat at Needham's 25th Annual Healthcare Conference. Serge Belanger, a senior analyst at Needham and Company, moderated the discussion with Fady I. Malik, executive vice president of research and development, and Andrew Callos, the company's

defenseworld.net - 2026-04-15 03:35:08